Cracking ALS & FTD: Translating Human Disease Biology into a Discovery Pipeline
- Why ALS and FTD demand a discovery first rethink, and how deep integration of genetics, clinical phenotypes, biomarkers, and longitudinal data reveals disease driving biology missed by traditional approaches
- Using human data to drive target identification and prioritisation, grounding ALS & FTD pipelines in patient relevant mechanisms from the outset
- Bridging ALS–FTD biology to inform shared and divergent pathways, and how this insight shapes programme strategy, indication selection, and translational confidence
- Building a scalable discovery engine for neurodegeneration, where integrated platforms accelerate progression from biological insight to pipeline ready therapeutic hypotheses